Journal
LANCET GLOBAL HEALTH
Volume 9, Issue 7, Pages E1017-E1021Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S2214-109X(21)00140-6
Keywords
-
Categories
Ask authors/readers for more resources
Multiple global efforts are underway to develop COVID-19 vaccines, with nine organisations announcing interim analyses from phase 3 clinical testing. The US Operation Warp Speed provided significant funding for vaccine development, raising questions about how these vaccines will be used in global health settings and addressing issues related to vaccine security, justice, equity, and diplomacy.
Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is: how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available